PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 29, 2026Cancers0 citationsOpen Access

Diagnostic Accuracy of 68GaGa-PSMA-11 PET-CT in Characterising Bone Lesions in Prostate Cancer: A Single-Centre Study

View Full Paper
ASAishani SachdevaMSMona SalemJJJohn Jenkins

Key Points

  • The study aims to evaluate the diagnostic accuracy of [68Ga]Ga-PSMA-11 PET-CT in characterizing bone lesions in prostate cancer patients.
  • Conducted a retrospective analysis involving 214 prostate cancer patients
  • Included only patients with follow-up imaging for assessment
  • Used multiple imaging modalities for final classification of lesions
  • Calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) based on follow-up imaging
  • Among 80 patients with metastatic bone lesions, 74 were confirmed, resulting in 92.5% accuracy.
  • Among 28 patients with benign lesions, 26 remained benign on follow-up, indicating 92.9% accuracy.
  • Indeterminate lesions showed four out of thirty-four were ultimately metastatic, highlighting diagnostic challenges.
  • Overall sensitivity was 97.4%, specificity was 86.7%, PPV was 94.9%, and NPV was 92.9%.

Abstract

Background: Precise staging of prostate cancer is vital for treatment planning and prognosis. While 68GaGa-PSMA-11 PET-CT has demonstrated high diagnostic accuracy in detecting metastatic disease, the interpretation of indeterminate or potentially benign PSMA-avid bone lesions remains a clinical challenge in routine practice. Methods: We conducted a retrospective single-centre study involving 214 patients who underwent 68GaGa-PSMA-11 PET-CT between January 2021 and January 2024. Patients with prior known bone metastases or alternative PSMA radiotracers were excluded. Only those with follow-up imaging were included for diagnostic accuracy analysis. Follow-up modalities included PSMA PET-CT, CT, MRI, and bone scintigraphy. Final classification (metastatic or benign) was based on radiological and clinical assessment. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated using follow-up imaging as the reference standard. Lesions classified as indeterminate were analysed separately and excluded from diagnostic performance calculations. Results: Of the 214 included patients, 142 had follow-up imaging. Among 80 patients with bone lesions initially reported as metastatic, 74 (92.5%) were confirmed. Among 28 patients initially reported as having benign bone lesions, 26 (92.9%) remained benign on follow-up. Thirty-four patients with indeterminate lesions were reviewed; four were ultimately metastatic. Excluding indeterminate cases, sensitivity, specificity, PPV, and NPV were 97.4%, 86.7%, 94.9%, and 92.9%, respectively. Diagnostic discordance was primarily associated with benign uptake in the ribs, iliac bones, pubic rami and degenerative changes. Conclusions: 68GaGa-PSMA-11 PET-CT shows excellent sensitivity and positive predictive value for detecting metastatic bone disease in prostate cancer. However, benign lesions may also exhibit uptake, emphasising the importance of integrating imaging results with PSA levels, Gleason scores, and TNM staging. Prospective studies are needed to validate these findings and assess their impact on long-term outcomes.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sachdeva et al. (2026) studied this question.

synapsesocial.com/papers/69c8c371de0f0f753b39e326https://doi.org/10.3390/cancers18071090
Ask AI
Helpful
Bookmark
Share
View Full Paper